Workflow
BHC(600721)
icon
Search documents
百花医药(600721) - 2015 Q1 - 季度财报
2015-04-22 16:00
Financial Performance - Operating revenue fell by 26.65% to CNY 139,253,739.15 year-on-year[7] - Net profit attributable to shareholders decreased by 429.95% to a loss of CNY 52,181,752.27[7] - Basic earnings per share dropped by 430.33% to -CNY 0.1941[7] - Net loss for Q1 2015 was ¥83,701,166.09, compared to a net loss of ¥11,854,851.83 in Q1 2014, representing a significant increase in losses[29] - Revenue for the current period is ¥6,624,931.31, a decrease of 40.5% compared to ¥11,049,873.81 in the previous period[31] - Net profit for the current period is ¥889,982.26, down 52.3% from ¥1,863,675.23 in the previous period[32] - Operating profit decreased to ¥1,250,262.22, a decline of 36.6% from ¥1,973,448.87 in the previous period[31] - Total profit for the current period is ¥1,287,777.13, a decrease of 43.1% from ¥2,261,470.10 in the previous period[31] Cash Flow - Cash flow from operating activities showed a significant decline of 119.47%, resulting in a negative cash flow of CNY 19,640,909.33[7] - Cash and cash equivalents decreased significantly to ¥4,366,198.24 from ¥28,763,264.81 at the beginning of the year, indicating liquidity challenges[23] - Cash inflow from financing activities is ¥276,000,000.00, compared to ¥104,736,300.00 in the previous period, indicating increased borrowing[34] - Cash outflow from financing activities totaled ¥323,875,163.28, up from ¥162,850,699.42 in the previous period[34] - Net cash flow from operating activities was $14,587,739.64, a decrease of 13.5% compared to $16,873,078.57 last period[37] - Total cash and cash equivalents decreased by $24,397,066.57 during the period[37] Assets and Liabilities - Total assets decreased by 1.89% to CNY 4,087,007,537.12 compared to the end of the previous year[7] - The total number of shareholders reached 13,782 at the end of the reporting period[12] - The total liabilities amount to RMB 3.17 billion, a slight increase from RMB 3.17 billion at the beginning of the year[21] - The ending balance of cash and cash equivalents is RMB 76.50 million, a decrease of RMB 75.83 million or 49.78% compared to the end of the previous year, mainly due to repayment of bank loans[14] - The ending balance of accounts payable is RMB 497.17 million, an increase of RMB 222.71 million or 81.15% compared to the end of the previous year, primarily due to increased raw material procurement[15] - The ending balance of prepaid accounts is RMB 127.93 million, an increase of RMB 62.92 million or 103.35% compared to the end of the previous year, mainly due to increased advance payments[15] Shareholder Information - The largest shareholder, Xinjiang Production and Construction Corps Sixth Division State-owned Assets Management Co., held 51.44% of shares[12] - The company repurchased 20,327,648 shares, accounting for 7.56% of the total share capital before the repurchase, at a total price of RMB 2.00[17] Management and Operational Insights - The management expenses for the period are RMB 53.81 million, an increase of RMB 23.16 million or 75.59% compared to the same period last year, mainly due to increased losses from subsidiaries[15] - The company has not disclosed any new product developments or market expansion strategies in this report[6] - The company has made adjustments to the comparative statements due to the consolidation of Xinjiang Baihua Hengxing Real Estate Development Co., Ltd. in August 2014[16] Government Support - The company reported a government subsidy of CNY 1,239,913.34 included in non-operating income[9]
百花医药(600721) - 2014 Q3 - 季度财报
2014-10-27 16:00
Financial Performance - Operating revenue for the first nine months was CNY 714,620,034.31, a decrease of 16.61% year-on-year[8] - Net profit attributable to shareholders was a loss of CNY 141,722,733.74, representing an increase in loss of 88.85% compared to the previous year[8] - Basic earnings per share were -0.5214 CNY, a decrease of 522.20% compared to the previous year[8] - Total operating revenue for the third quarter was ¥279,155,527.61, a decrease of 7.5% compared to ¥300,675,618.16 in the same period last year[31] - Total operating costs increased to ¥414,485,372.68, up 29.8% from ¥319,174,440.72 year-over-year[31] - Net loss for the third quarter was ¥131,694,882.88, compared to a loss of ¥18,653,289.62 in the same quarter last year[32] - Operating profit for the third quarter was a loss of ¥135,379,967.27, compared to a loss of ¥18,505,734.16 in the previous year[32] - The company reported a significant increase in asset impairment losses, which rose to ¥24,280,542.43 from ¥4,828,448.49 year-over-year[31] - The company reported a net loss of CNY 80,351,408.03 in retained earnings, compared to a profit of CNY 59,818,409.30 at the beginning of the year[26] Assets and Liabilities - Total assets decreased by 3.41% to CNY 4,385,008,227.38 compared to the end of the previous year[7] - Total liabilities increased from CNY 3,166,326,222.79 to CNY 3,237,265,948.96, an increase of approximately 2.2%[26] - The ending balance of accounts receivable is 139 million yuan, an increase of 39.52% compared to the previous year, mainly due to an increase in receivables from sales[12] - The ending balance of notes receivable is 29.95 million yuan, a decrease of 74.85% compared to the previous year, primarily due to the maturity of bank acceptance bills[12] - The ending balance of deferred tax assets is 19.08 million yuan, an increase of 37.68% compared to the previous year, mainly due to the provision for impairment made by subsidiaries[13] - The ending balance of long-term payables is 293 million yuan, an increase of 109.14% compared to the previous year, mainly due to increased equipment financing lease payments from subsidiaries[13] - The ending balance of special payables is 28.29 million yuan, an increase of 62.56% compared to the previous year, mainly due to funds received for urban renovation projects[14] - The ending balance of accounts payable is 102.10 million yuan, an increase of 256.99% compared to the previous year, mainly due to increased notes from subsidiaries[13] Cash Flow - Cash flow from operating activities decreased by 19.39% to CNY 97,105,640.31 for the first nine months[7] - Cash flow from investment activities is -29.13 million yuan, an increase of 62.08% compared to the previous year, mainly due to reduced cash payments for fixed assets and intangible assets[15] - Cash inflow from operating activities for the first nine months of 2014 was CNY 169,927,300.95, an increase from CNY 116,889,012.02 in the same period last year, representing an increase of approximately 45.2%[40] - Net cash flow from operating activities for Q3 2014 was CNY 97,105,640.31, compared to CNY 120,457,394.23 in the same period last year, reflecting a decrease of approximately 19.3%[37] - Cash inflow from financing activities in Q3 2014 was CNY 1,234,396,300.00, significantly higher than CNY 885,527,744.43 in the prior year, marking an increase of approximately 39.3%[38] - The net increase in cash and cash equivalents for Q3 2014 was CNY 88,256,906.45, down from CNY 148,887,105.23 in the same quarter last year, indicating a decrease of approximately 40.6%[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 14,136[10] - The largest shareholder, the Sixth Division of the Xinjiang Production and Construction Corps, holds 48.78% of shares[10] - The company expects a cumulative net profit for the year to be a loss, influenced by the downturn in the "coal-coke-steel" and "coal-coke-chemical" industry chains[17]
百花医药(600721) - 2014 Q2 - 季度财报
2014-08-19 16:00
Financial Performance - In the first half of 2014, the company produced 352,300 tons of raw coal, a decrease of 38.08% compared to 569,000 tons in the same period last year[20]. - The company's total operating revenue for the first half of 2014 was CNY 435.46 million, a decrease of 21.72% from CNY 556.26 million in the previous year[18]. - The net profit attributable to shareholders of the listed company was CNY -52.21 million, a decrease of 481.67% compared to CNY 13.68 million in the same period last year[18]. - The company reported a total profit loss of CNY 77,557,500, a significant decline from a profit of CNY 31,319,200 in the previous year, mainly due to reduced production and sales volumes in subsidiaries[29]. - The company reported a net loss of -52,206,829.17 RMB for the current period, compared to -24,960,396.84 RMB in the previous period[82]. - The net profit for the current period is CNY 24,534,731.03, compared to CNY 13,678,497.89 in the same period last year, representing an increase of approximately 79.5%[86]. Assets and Liabilities - The company’s total assets as of June 30, 2014, were CNY 4.34 billion, a decrease of 2.15% from CNY 4.44 billion at the end of the previous year[18]. - The company’s total liabilities were CNY 3.07 billion, a decrease of 0.61% from the previous year-end[20]. - The company’s net assets decreased by 5.31% to CNY 924.25 million compared to CNY 976.03 million at the end of the previous year[18]. - The company’s cash flow from operating activities increased by 109.48% to CNY 91.69 million compared to CNY 43.77 million in the same period last year[18]. - The company’s total current assets as of June 30, 2014, amounted to 864,089,285.93 RMB, compared to 854,940,908.36 RMB at the beginning of the year, showing an increase[61]. - The company’s inventory as of June 30, 2014, was 308,501,757.94 RMB, up from 287,649,156.96 RMB at the beginning of the year[61]. Revenue Breakdown - Coal mining revenue was CNY 83,153,683.24, down 31.09% year-on-year, with a gross margin of 35.96%, an increase of 2.66 percentage points[31]. - Coking revenue decreased to CNY 164,289,580.59, down 17.07% year-on-year, with a gross margin of 19.58%, a decrease of 8.53 percentage points[31]. - Urea revenue was CNY 75,294,849.20, down 34.59% year-on-year, with a negative gross margin of -18.90%, a decrease of 8.20 percentage points[31]. - Domestic sales amounted to CNY 427,863,516.61, reflecting a decline of 21.18%[33]. Cash Flow and Financing - The net cash flow from operating activities increased by 109.48% to CNY 91,685,885.98, attributed to a reduction in operating payables[27]. - The net cash flow from financing activities decreased by 57.11% to CNY 14,101,666.30, reflecting reduced cash inflows from financing activities[28]. - Cash flow from operating activities generated a net inflow of ¥91.69 million, an increase from ¥43.77 million in the previous period[73]. - Cash inflow from financing activities increased to 55,000,000.00 RMB from 50,000,000.00 RMB, marking a 10% rise[78]. Inventory and Receivables - The company’s inventory increased significantly from CNY 5,641,811.52 to CNY 15,809,447.55, a rise of approximately 180.5%[64]. - The balance of other receivables at the end of the period is CNY 55,123,978.64, with a bad debt provision of CNY 10,689,519.66, representing 19.39% of the total[194]. - The aging analysis shows that 73,151,090.84 RMB (74.10%) of accounts receivable is within one year, with a bad debt provision of 3,663,691.53 RMB[188]. Corporate Governance and Shareholder Information - The total number of shareholders at the end of the reporting period was 13,717[56]. - The largest shareholder, the State-owned Assets Management Company of the 6th Agricultural Division, held 48.78% of the shares, totaling 131,133,741 shares[56]. - The company did not implement any profit distribution plan during the reporting period[37]. - The company plans to compensate shareholders through share repurchase if approved by the shareholders' meeting[48]. Operational Strategies - The company plans to strengthen sales efforts to reduce inventory and alleviate cash flow pressures following the increased production capacity of fertilizer[24]. - The company is actively seeking new projects and external support to create new economic growth points amid challenging market conditions[24]. - The company aims to enhance internal control and financial budget management to mitigate operational risks[24]. Accounting Policies and Practices - The financial statements comply with the enterprise accounting standards, reflecting the company's financial status accurately[104]. - The company prepares consolidated financial statements in accordance with the relevant accounting standards, ensuring consistency in accounting policies across subsidiaries[110]. - The company recognizes impairment losses for available-for-sale financial assets when there is a significant decline in fair value[121]. Taxation and Subsidies - The main tax rates applicable include a 25% corporate income tax and a 17% VAT for general taxpayers[169]. - The company is eligible for a reduced corporate income tax rate of 15% for certain projects in the western region, provided that over 70% of its revenue comes from these projects[172].
百花医药(600721) - 2013 Q4 - 年度财报
2014-04-27 16:00
Financial Performance - In 2013, the company's operating income was CNY 1,181,709,696.47, representing a 5.62% increase compared to CNY 1,118,869,820.05 in 2012[17]. - The net profit attributable to shareholders was CNY 2,991,697.55, a significant decrease of 85.38% from CNY 20,465,356.27 in the previous year[17]. - The net cash flow from operating activities dropped by 98.06% to CNY 6,631,614.98 from CNY 342,002,939.75 in 2012[17]. - The total assets at the end of 2013 were CNY 4,438,680,081.44, a slight increase of 0.47% from CNY 4,418,125,616.02 in 2012[17]. - The company's net assets attributable to shareholders increased by 3.66% to CNY 976,033,725.03 from CNY 941,595,343.22 in 2012[17]. - Basic earnings per share decreased by 85.41% to CNY 0.0111 from CNY 0.0761 in 2012[17]. - The weighted average return on net assets fell to 0.32%, a decrease of 1.87 percentage points from 2.19% in 2012[17]. - Operating revenue reached 1.182 billion RMB, an increase of 5.62% compared to the previous year[26]. - Net profit was 5.8227 million RMB, with a net profit attributable to shareholders of the parent company of 2.9917 million RMB[20]. - The company reported a significant increase in other operating income, rising by 512.69% to 58.2444 million RMB[26]. - The company reported a net profit of CNY 5,822,652.55, a significant decrease from CNY 41,961,333.70 in the previous year, indicating a decline of approximately 86.1%[123]. Operational Highlights - The company has established a production capacity of 1.6 million tons of raw coal, 800,000 tons of coke, and 210,000 tons of urea annually[15]. - The company produced 1.216 million tons of raw coal, 604,400 tons of coke, 141,400 tons of urea, and 11,900 tons of crude benzene during the reporting period[20]. - The production of raw coal increased by 192,473.00 tons, representing an 18.81% increase year-on-year, while sales volume increased by 292,453.57 tons, a growth of 30.80%[30]. - The sales volume of coke increased by 119,591.78 tons, a growth of 21.39% compared to the previous year, while the sales volume of urea increased by 15,479.48 tons, a growth of 16.49%[30]. Strategic Initiatives - The company implemented a "big resource" development strategy to stabilize its main business and explore new industry breakthroughs[20]. - The company aims to accelerate the implementation of its "Big Resource" strategy, focusing on resource extension and regional advantages for industry breakthroughs[55]. - The company plans to achieve operating revenue of CNY 1.337 billion in 2014, with coal revenue projected at CNY 280 million, coke at CNY 417 million, and other chemical products at CNY 406 million[55]. - The company aims to enhance its operational efficiency and explore potential mergers and acquisitions to drive future growth[136]. Financial Management - The company focused on enhancing internal control and financial management to ensure stable operations[21]. - The company has a total funding requirement of CNY 802 million for major construction projects in 2014, including the restoration and technical transformation of the Yuxin Coal Mine No. 7[59]. - Operating funds required for 2014 amount to CNY 1.626 billion, covering raw material procurement, wages, and taxes for various subsidiaries[59]. - The company has commitments related to profit forecasts for the years 2010 to 2013, with projected net profits of 69,904,000 CNY, 68,785,600 CNY, 68,785,600 CNY, and 68,785,600 CNY respectively[72]. Market Conditions - The coal industry remains under pressure due to oversupply and declining prices, with expectations for slow recovery in the short term[52]. - The company has identified market risks due to increased competition and potential price declines in coal and coke products, necessitating timely adjustments in operational strategies[60]. Shareholder Information - The total number of shares is 268,851,955, with 55.38% (148,893,460 shares) being restricted shares and 44.62% (119,958,495 shares) being unrestricted shares[77]. - The largest shareholder is Xinjiang Production and Construction Corps with 48.78% (131,133,741 shares) of the total shares[80]. - The total number of shareholders at the end of the reporting period is 15,395, an increase from 14,703 in the previous reporting period[80]. Governance and Management - The company’s board includes independent directors with diverse backgrounds in law and finance, enhancing governance[90]. - The management team has extensive experience in various industries, contributing to strategic decision-making[91]. - The company has maintained stable leadership with no changes in key positions during the reporting period[88]. - The company has a strict internal control system in place to enhance risk management capabilities[97]. Accounting Policies - The company adheres to the accounting policies and estimates as per the Chinese Accounting Standards, reflecting its financial position and performance accurately[154]. - The company uses the calendar year as its accounting period, from January 1 to December 31[155]. - The company follows specific accounting treatments for mergers and acquisitions, distinguishing between mergers under common control and those not under common control[159]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development[136]. - The financial results indicate a strong performance in the face of market challenges, with a focus on sustainable growth strategies[136].
百花医药(600721) - 2014 Q1 - 季度财报
2014-04-27 16:00
Financial Performance - Operating revenue for the first quarter was CNY 189,307,645.78, a decrease of 40.83% year-on-year[8] - Net profit attributable to shareholders was a loss of CNY 10,036,494.39, an improvement of 30.68% compared to the previous year's loss[8] - Basic earnings per share improved by 30.80% to -CNY 0.0373 from -CNY 0.0539 in the previous year[8] - Total operating revenue for the current period is 189,307,645.78, down from 319,943,906.36 in the previous period, representing a decrease of approximately 40.7%[25] - Total operating costs decreased to 199,160,559.49 from 325,882,056.45, a reduction of about 38.9%[25] - Net profit for the current period is -12,227,415.46, compared to -8,671,088.79 in the previous period, indicating a worsening of approximately 40.5%[26] - Operating profit for the current period is -9,932,801.31, worsening from -6,215,707.01 in the previous period, indicating a decline of approximately 60.1%[25] - The company’s total profit is -9,361,050.29, compared to -5,513,460.62 in the previous period, reflecting a decline of about 69.5%[25] Cash Flow - Net cash flow from operating activities increased significantly to CNY 71,906,180.58, compared to a negative cash flow of CNY -2,021,501.52 in the same period last year, representing a 3,657.07% increase[8] - Cash flow from operating activities generated a net amount of 71,906,180.58, a significant recovery from -2,021,501.52 in the previous period[30] - Cash inflow from financing activities was ¥6,000,000.00, with cash outflow for dividend distribution and interest payments totaling ¥1,596,000.01, resulting in a net cash flow of ¥4,403,999.99[34] - The net increase in cash and cash equivalents for the period was ¥21,131,779.43, compared to ¥5,388,202.45 in the previous period, indicating strong liquidity growth[35] - Cash received from operating activities related to other business activities surged to ¥30,305,840.29, compared to just ¥2,914,052.30 previously, marking a substantial increase[33] - Total cash outflow for operating activities was ¥32,233,643.77, which is a 164.5% increase from ¥12,178,485.64 in the last period[33] - Investment activities resulted in a net cash outflow of ¥145,299.13, an improvement from a net outflow of ¥385,009.00 in the previous period[34] Assets and Liabilities - Total assets decreased by 1.05% to CNY 4,392,105,963.45 compared to the end of the previous year[8] - Total current assets increased to CNY 901,713,971.76 from CNY 854,940,908.36, representing a growth of approximately 5.5%[16] - Accounts receivable rose to CNY 106,849,632.63 from CNY 99,625,492.81, an increase of about 7.3%[16] - Inventory increased significantly to CNY 338,962,892.46 from CNY 287,649,156.96, reflecting a growth of approximately 17.9%[16] - Total liabilities decreased to CNY 3,047,391,025.23 from CNY 3,086,577,843.38, a reduction of about 1.3%[18] - Total equity decreased slightly to CNY 1,344,714,938.22 from CNY 1,352,102,238.06, a decline of approximately 0.5%[18] - Cash and cash equivalents decreased to CNY 184,602,874.01 from CNY 204,906,291.66, a decline of about 9.9%[16] - Short-term borrowings decreased to CNY 693,000,000.00 from CNY 749,200,000.00, a reduction of approximately 7.5%[18] - Non-current assets totaled CNY 3,490,391,991.69, down from CNY 3,583,739,173.08, a decrease of approximately 2.6%[17] Shareholder Information - The total number of shareholders as of the report date was 14,220[12] - The largest shareholder, Xinjiang Sixth Division State-owned Assets Management Co., Ltd., holds 48.78% of the shares[12] Government Subsidies - The company reported a total of CNY 967,591.34 in government subsidies related to its regular business operations[9] Financial Statements - The financial statements for the first quarter have not been audited[6]